Transforming growth factor betas and their signaling receptors in human hepatocellular carcinoma - PubMed (original) (raw)
Comparative Study
Transforming growth factor betas and their signaling receptors in human hepatocellular carcinoma
M Abou-Shady et al. Am J Surg. 1999 Mar.
Abstract
Background: Transforming growth factor betas (TGF-betas) are multifunctional polypeptides that have been suggested to influence tumor growth. They mediate their functions via specific cell surface receptors (type I ALK5 and type II TGF-beta receptors). The aim of this study was to analyze the roles of the three TGF-betas and their signaling receptors in human hepatocellular carcinoma (HCC).
Methods: HCC tissue samples were obtained from 18 patients undergoing partial liver resection. Normal liver tissues from 7 females and 3 males served as controls. The tissues for histological analysis were fixed in Bouin's solution and paraffin embedded. For RNA analysis, freshly obtained tissue samples were snap frozen in liquid nitrogen and stored at -80 degrees C until used. Northern blot analysis was used in normal liver and HCC to examine the expression of TGF-beta1, -beta2, -beta3 and their receptors: type I ALK5 (TbetaR-I ALK5), type II (TbetaR-II), and type III (TbetaR-III). Immunohistochemistry was performed to localize the corresponding proteins.
Results: All three TGF-betas demonstrated a marked mRNA overexpression in HCC in comparison with normal controls, whereas the levels of all three TGF-beta receptors showed no significant changes. Intense TGF-beta1, TGF-beta2, and TGF-beta3 immunostaining was found in hepatocellular carcinoma cells and in the perineoplastic stroma with immunohistochemistry, whereas no or mild immunostaining was present in the normal liver. For TbetaR-I ALK5 and TbetaR-II, the immunostaining in both HCC and normal liver was mild to moderate, with a slightly higher intensity in the normal tissues.
Conclusion: The upregulation of TGF-betas in HCC suggests an important role for these isoforms in hepatic carcinogenesis and tumor progression. Moreover, the localization of the immunoreactivity in both malignant hepatocytes and stromal cells suggests that TGF-betas act via autocrine and paracrine pathways in this neoplasm.
Similar articles
- Transforming growth factor betas and their receptors in human liver cirrhosis.
Baer HU, Friess H, Abou-Shady M, Berberat P, Zimmermann A, Gold LI, Korc M, Büchler MW. Baer HU, et al. Eur J Gastroenterol Hepatol. 1998 Dec;10(12):1031-9. doi: 10.1097/00042737-199812000-00009. Eur J Gastroenterol Hepatol. 1998. PMID: 9895050 - Role of transforming growth factor-beta1-smad signal transduction pathway in patients with hepatocellular carcinoma.
Ji GZ, Wang XH, Miao L, Liu Z, Zhang P, Zhang FM, Yang JB. Ji GZ, et al. World J Gastroenterol. 2006 Jan 28;12(4):644-8. doi: 10.3748/wjg.v12.i4.644. World J Gastroenterol. 2006. PMID: 16489684 Free PMC article. - Transforming growth factor beta receptors in verrucous and squamous cell carcinoma.
Anderson M, Muro-Cacho C, Cordero J, Livingston S, Muñoz-Antonia T. Anderson M, et al. Arch Otolaryngol Head Neck Surg. 1999 Aug;125(8):849-54. doi: 10.1001/archotol.125.8.849. Arch Otolaryngol Head Neck Surg. 1999. PMID: 10448730 - TGF-betas and TGF-beta receptors in atherosclerosis.
McCaffrey TA. McCaffrey TA. Cytokine Growth Factor Rev. 2000 Mar-Jun;11(1-2):103-14. doi: 10.1016/s1359-6101(99)00034-9. Cytokine Growth Factor Rev. 2000. PMID: 10708958 Review. - Molecular mechanisms of inactivation of TGF-beta receptors during carcinogenesis.
Kim SJ, Im YH, Markowitz SD, Bang YJ. Kim SJ, et al. Cytokine Growth Factor Rev. 2000 Mar-Jun;11(1-2):159-68. doi: 10.1016/s1359-6101(99)00039-8. Cytokine Growth Factor Rev. 2000. PMID: 10708963 Review.
Cited by
- TGF-β signaling in liver and gastrointestinal cancers.
Katz LH, Likhter M, Jogunoori W, Belkin M, Ohshiro K, Mishra L. Katz LH, et al. Cancer Lett. 2016 Sep 1;379(2):166-72. doi: 10.1016/j.canlet.2016.03.033. Epub 2016 Mar 30. Cancer Lett. 2016. PMID: 27039259 Free PMC article. Review. - Overexpression of squamous cell carcinoma antigen variants in hepatocellular carcinoma.
Pontisso P, Calabrese F, Benvegnù L, Lise M, Belluco C, Ruvoletto MG, Marino M, Valente M, Nitti D, Gatta A, Fassina G. Pontisso P, et al. Br J Cancer. 2004 Feb 23;90(4):833-7. doi: 10.1038/sj.bjc.6601543. Br J Cancer. 2004. PMID: 14970861 Free PMC article. - Transforming growth factor-beta signaling promotes hepatocarcinogenesis induced by p53 loss.
Morris SM, Baek JY, Koszarek A, Kanngurn S, Knoblaugh SE, Grady WM. Morris SM, et al. Hepatology. 2012 Jan;55(1):121-31. doi: 10.1002/hep.24653. Epub 2011 Dec 6. Hepatology. 2012. PMID: 21898503 Free PMC article. - The immunosuppressive tumor microenvironment in hepatocellular carcinoma.
Pang YL, Zhang HG, Peng JR, Pang XW, Yu S, Xing Q, Yu X, Gong L, Yin YH, Zhang Y, Chen WF. Pang YL, et al. Cancer Immunol Immunother. 2009 Jun;58(6):877-86. doi: 10.1007/s00262-008-0603-5. Epub 2008 Oct 22. Cancer Immunol Immunother. 2009. PMID: 18941744 Free PMC article. - Expression of transforming growth factor β1 promotes cholangiocarcinoma development and progression.
Huang CK, Aihara A, Iwagami Y, Yu T, Carlson R, Koga H, Kim M, Zou J, Casulli S, Wands JR. Huang CK, et al. Cancer Lett. 2016 Sep 28;380(1):153-62. doi: 10.1016/j.canlet.2016.05.038. Epub 2016 Jun 27. Cancer Lett. 2016. PMID: 27364974 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical